Study Title
A Phase 1/2, Open-label Study to Assess Safety, Tolerability, Biodistribution, Radiation Dosimetry and PET Imaging Characteristics of [18F]FPyGal in Comparison to in Vitro Diagnostics for the Assessment of Senescence in Oncological Patients
Study Details
Description:
It is of particular interest to find out whether it is possible to use the novel radiotracer [18F]FPyGal to be tested to detect areas after standard tumor therapy that contain resistant (therapy-resistant) tumor cells. This resistance phenomenon in tumor tissues, which may be visualized with the radiotracer [18F]FPyGal, is called tumor senescence.
Sponsor:
University Hospital Tuebingen
Contacts:
Christian la Fougere, MDchristian.lafougere@med.uni-tuebingen.de
+49-7071 29-0
Ulrich M Lauer, MDulrich.lauer@med.uni-tuebingen.de
+49-7071 29-0
Government Study Link:
NCT04536454 - Click here to see study onClinicalTrials.gov